XML 21 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Noncontrolling Interests
IDT Corp
Additional Paid-In Capital
IDT Corp
Treasury Stock
IDT Corp
Accumulated Other Comprehensive Income and Loss
IDT Corp
Accumulated Deficit
IDT Corp
Class A Common Stock
IDT Corp
Class B Common Stock
Beginning Balance at Jul. 31, 2015 $ 134,940 $ 1,109 $ 403,146 $ (110,543) $ 771 $ (159,829) $ 33 $ 253
Beginning Balance, Shares at Jul. 31, 2015             3,272 25,276
Dividends declared (17,358) (17,358)
Restricted Class B common stock purchased from employees (134) (134)
Repurchases of Class B common stock through repurchase program (4,639) (4,639)
Exercise of subsidiary stock options 9 9
Stock-based compensation $ 2,680 2,680
Restricted stock issued to employees and directors, Shares           12
Stock issued for matching contributions to the 401(k) Plan $ 1,411 1,410 $ 1
Stock issued for matching contributions to the 401(k) Plan, Shares             95
Sale of Zedge equity prior to the spin-off 374 374
Distributions to noncontrolling interests (1,834) (1,834)
Zedge/Rafael Spin-Off (11,062) (722) (11,369)   1,029      
Other 2 2
Other comprehensive loss (5,544) (5,544)
Net income for the year 25,358 1,844 23,514
Ending Balance at Jul. 31, 2016 124,203 406 396,243 (115,316) (3,744) (153,673) $ 33 $ 254
Ending Balance, Shares at Jul. 31, 2016             3,272 25,383
Dividends declared (17,874) (17,874)
Restricted Class B common stock purchased from employees (1,838) (1,838)
Exercise of stock options 836 835 $ 1
Exercise of stock options, Shares               73
Stock-based compensation 3,740 3,739 $ 1
Stock-based compensation, Shares               105
Sale of Class B common stock to Howard S. Jonas 24,930 (8,920) 33,850
Sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas (see Note 2) 1,000 1,185 (185)
Issuance of member interests in CS Pharma Holdings, LLC (see Note 2) 10,000 7,250 2,750          
Distributions to noncontrolling interests (1,482) (1,482)
Other comprehensive loss 1,401 1,401
Net income for the year 9,641 1,464 8,177
Ending Balance at Jul. 31, 2017 154,557 8,823 394,462 (83,304) (2,343) (163,370) $ 33 $ 256
Ending Balance, Shares at Jul. 31, 2017             3,272 25,561
Dividends declared (13,941)         (13,941)    
Restricted Class B common stock purchased from employees (362)     (362)        
Repurchases of Class B common stock through repurchase program (1,931)     (1,931)        
Stock-based compensation 3,581   3,581        
Stock-based compensation, Shares               33
Transfer of right to receive equity to Howard S. Jonas (40) (40)            
Consolidation of Lipomedix Pharmaceuticals, Inc. 558 558            
Distributions to noncontrolling interests (1,040) (1,040)            
Zedge/Rafael Spin-Off (114,919) (8,653) (103,996)   (2,270)      
Other comprehensive loss (359)       (359)      
Net income for the year 5,199 991       4,208    
Ending Balance at Jul. 31, 2018 $ 31,303 $ 639 $ 294,047 $ (85,597) $ (4,972) $ (173,103) $ 33 $ 256
Ending Balance, Shares at Jul. 31, 2018             3,272 25,594